Related Compounds
Compounds connected by the same goals, effects, or research topics.
Compound Profile
Berberine
Insulin resistance context; triglyceride/LDL support; safety screen: pregnancy; breastfeeding; diabetes medications; CYP/P gp medication review.
Use extra caution — Safety evidence: gastrointestinal adverse effects are most commonly reported. Details
Last reviewed: •4 sources citedReport a correctionProfile-wide ·A Strong
Verdict: BerberineSituation-dependent
Best for
- Metabolic support — fasting glucose and lipid markers
- Insulin-resistance patterns, including in PCOS
- People who can space it away from other medications
Not ideal for
- Weight loss on its own — the "natural Ozempic" framing far outruns the evidence
- Anyone taking medications cleared by CYP3A4 or P-glycoprotein
- Pregnancy, breastfeeding, and infants
- Evidence confidence
- Moderate–strong for metabolic markers, but interaction risk drives the decision
- Expected onset
- Gradual — metabolic markers shift over weeks
- Give it
- 8–12 weeks, judged on bloodwork rather than how you feel
Bottom line: One of the few supplements with repeated meta-analytic support for glucose and lipid markers — but it behaves pharmacologically, interacts with common medications, and frequently upsets the gut. Treat it as a drug-like agent to discuss with a clinician, not a casual daily addition.
Safety: Berberine inhibits CYP3A4 and P-glycoprotein, so it can raise levels of many prescription drugs. GI upset is common. Avoid in pregnancy, breastfeeding, and infants. Review it with a clinician or pharmacist before combining it with anything prescribed.
On the evidence: Multiple meta-analyses of randomized trials report improvements in fasting glucose, HbA1c, and LDL — though much of the trial base is small, short, and geographically concentrated.
Consider instead: Inositol — for PCOS-related insulin resistance with a far gentler interaction profile
How strong is the evidence?Moderate–high (metabolic markers)
Why not higher
- Most trials are small, short, and concentrated in a few regions
- Reporting quality is uneven and publication bias is plausible
- Long-term outcome data — not just marker changes — is largely missing
Why not lower
- Several independent meta-analyses of randomized trials point the same direction
- The mechanism (AMPK activation and gut-microbiome effects) is well characterized
- Effect sizes on glucose and lipid markers are clinically meaningful, not trivial
Practical takeaway: If the goal is metabolic markers and a clinician has cleared the interaction picture, an 8–12 week trial judged on bloodwork is reasonable. If the goal is weight loss alone, expectations should be low.
Next stepsWhere to go next — guides & comparisons
Start here
New to this? Begin with Berberine and weight loss.
Compare first
- Berberine vs. metformin — if you want to understand how the evidence bases compare — a conversation for your prescriber, not a substitution to make on your own
- Berberine vs. inositol — if the target is PCOS or insulin resistance and tolerability matters
Continue reading
- If you want to browse more compounds → All compounds
Quick stats
- Evidence level
- Strong evidence
- Typical onset
- Varies by prep
- Safety rating
- Use extra caution: Interaction risk
- Best for
- AMPK, Glucose Transporters
- Avoid / review if
- Pregnancy, Breastfeeding
Botanical Context
Source botanicals and comparison guides related to Berberine.
Found in
Compare active botanicals
Safety
Safety & Cautions
High caution
Caution level: High. Multiple caution categories apply, or the record uses avoid/contraindication language.
- Interaction-AwareMedication or interaction context is explicitly noted.
- Liver-SensitiveLiver-related caution language appears in the profile.
- Pregnancy/Breastfeeding CautionPregnancy or breastfeeding caution language is present.
- Safety evidence
- gastrointestinal adverse effects are most commonly reported
- Who should avoid this?
- Pregnancy; Breastfeeding
- Talk to a professional if
- you use relevant medications, you are pregnant or breastfeeding.
Avoid during pregnancy, breastfeeding, and in infants; repeated human dosing inhibited CYP2D6, CYP2C9, and CYP3A4, and a clinical cyclosporine interaction is documented, so medication review is important.
Evidence Summary
Profile-wide ·A StrongEvidence lens
Most useful for practical interpretation when safety context also fits.
StrongStrong evidence
Human clinical evidence: Present in source signals
Mechanistic / preclinical: Mechanism mapped — Inflammatory Signaling Modulation · Metabolic Regulation · AMPK Signaling
Research maturity: Established research — main contexts: AMPK · Glucose Transporters
Safety boundary: Safety note available — Safety evidence: gastrointestinal adverse effects are most commonly reported.
This profile cites 4 human studies.
Evidence Strength
Confidence estimate based on the design quality and consistency of published clinical trials.
Berberine has a strong evidence rating.
General wellnessGeneral wellness
Citation density
6.0
Sources
12
Effects
2
Research recency
Mixed recency
Evidence Grade
Grade A: Strong Evidence
Evaluation of methodological rigor, population reach, and evidence alignment.
- Design Match
- Meta analysis
- Risk of Bias
- Low
- Consistency
- Consistent
Strongest recorded design is a meta analysis, drawn from 13 recorded studies, 13 in people. No disagreement is recorded across them.
How evidence grades work
Each grade reflects the strength and consistency of published human evidence — not marketing claims. Grades are based on study count, design quality, effect size, consistency, and recency.
- Strong
- Multiple RCTs, consistent direction, adequate effect size
- Moderate
- Some RCTs or consistent observational data in humans
- Preliminary / Mixed
- Animal or in-vitro only, or conflicting human data
- Traditional / Theoretical
- Traditional use only; no controlled human trials
Clinical Study Summaries (12)8 human evidence sources · 4 human trials · ~84 participants across 1 human evidence source with reported N · Consistency not yet classifiable
Filter by study class
Showing 12 of 12 studies.
What the evidence actually shows
This table contains 12 structured sources, including 8 human evidence sources; 4 are human trials. Across 1 human evidence source with a reported sample size, the approximate participant total is 84; overlapping publications may include some of the same people.
| Study | Design | N | Dose | Duration | Population | Outcome | Result & magnitude | Source |
|---|---|---|---|---|---|---|---|---|
The effect of berberine on obesity indices: a systematic review and meta-analysis Background | Meta-analysis Statistically combines results from multiple eligible studies; confidence still depends on the quality, consistency, and directness of those studies. | — | — | — | — | — | Modest pooled reductions in weight, BMI, and waist circumference; no clear waist-to-hip-ratio effect. | PubMed → |
Background | Meta-analysis Statistically combines results from multiple eligible studies; confidence still depends on the quality, consistency, and directness of those studies. | — | — | — | — | — | Pooled evidence favored triglycerides, fasting glucose, waist circumference, LDL, total cholesterol, BMI, and 2-hour glucose; HDL and BP were not clearly improved. | PubMed → |
Background | Meta-analysis Statistically combines results from multiple eligible studies; confidence still depends on the quality, consistency, and directness of those studies. | — | — | — | — | — | Weight, BMI, waist circumference, total cholesterol, triglycerides, and fasting glucose improved; LDL, HDL, HbA1c, and BP did not clearly improve. | PubMed → |
Background | Systematic review Uses a predefined method to find and evaluate relevant studies, but may or may not pool their results statistically. | — | — | — | — | — | Clinical evidence suggested a fasting-glucose signal, while much broader biochemical evidence came from preclinical studies. | PubMed → |
Efficacy of berberine in patients with type 2 diabetes mellitus PubMed · Metabolism · 2008 Background | Randomized controlled trial Randomly assigns participants to interventions or controls, reducing many sources of bias when the trial is conducted well. | n=84 | — | — | — | — | — | PubMed → |
Background | Randomized controlled trial Randomly assigns participants to interventions or controls, reducing many sources of bias when the trial is conducted well. | — | — | — | — | — | Berberine reduced atherogenic lipids, apoB, and Lp(a), with larger lipid changes reported in women than men. | PubMed → |
Show 6 more studies
Background | Randomized controlled trial Randomly assigns participants to interventions or controls, reducing many sources of bias when the trial is conducted well. | — | — | — | — | — | Adds contemporary randomized evidence on adiposity/metabolic outcomes in obesity with MASLD; use full trial effect estimates before publication. | Exploratory secondary findings included reductions in LDL-C (~7.72 mg/dL), apoB (~3.42 mg/dL), and hs-CRP (~0.072 mg/dL) versus placebo. | PubMed → |
Lipid-lowering effect of berberine in human subjects and rats PubMed · Phytomedicine · 2012 Background | Controlled trial Compares an intervention with a control group but may lack random assignment or other safeguards of a strong randomized trial. | — | — | — | — | — | — | PubMed → |
Background | Narrative review Summarizes selected literature without the full prespecified search and selection methods of a systematic review. | — | — | — | — | — | Higher-level pooled evidence supports improvements in selected glycemic and inflammatory biomarkers. | PubMed → |
Association of human papillomavirus type 58 with breast cancer in Shaanxi province of China PubMed · J Med Virol · 2015 Background | Other / unclear The study design is not yet classified clearly enough to infer its place in the evidence hierarchy. | — | — | — | — | — | — | PubMed → |
PubMed · MMWR Morb Mortal Wkly Rep · 2011 Background | Other / unclear The study design is not yet classified clearly enough to infer its place in the evidence hierarchy. | — | — | — | — | — | — | PubMed → |
Background | Other / unclear The study design is not yet classified clearly enough to infer its place in the evidence hierarchy. | — | — | — | — | — | A berberine-response signature was associated with lower IHD and diabetes risk in Mendelian-randomization analyses (IHD OR 0.85, 95% CI 0.79-0.91; diabetes OR 0.88, 0.80-0.96). | PubMed → |
How Berberine Works
Simplified mechanism pathway based on preclinical and pharmacological evidence. Does not confirm clinical efficacy.
Mechanism Pathway — How Berberine Works
CompoundTarget / ReceptorMechanismEffect / Outcome
Dosing
- Common form
- capsule or standardized extract
- No standardized dose
- Our source data records the usual product form for this ingredient but no studied dose. Preparations differ widely, so follow the standardization on the product you actually have and speak to a clinician before starting.
Mechanisms & biological pathways
Preclinical mechanism details from scientific profiles; these represent plausible pathways but do not guarantee clinical efficacy in humans.
- Inflammatory Signaling Modulation
- Metabolic Regulation
- AMPK Signaling
- Glucose Metabolism Support
- Lipid Metabolism Support
Guides that use Berberine
Goal guides
Condition guides
Continue exploring
Related research paths
Related Herbs
Botanicals connected by the same goals, effects, or research topics.
Related Guides
Deeper context, comparisons, and practical research paths.
Related Safety Pages
Safety checks and cautions relevant to this decision.
Related Articles
Deeper context, comparisons, and practical research paths.
Compare & Sourcing
Compare side-by-side tradeoffs or verify active marker guidelines.
Related alternatives
Herbs for similar conditions
Tradeoffs
Free safety checklist
Get the Berberine evidence notes
Occasional research updates, safety context, and product-quality checks for supplement decisions.
We use your email to send the checklist and occasional evidence-first supplement updates. Unsubscribe anytime. Privacy policy.
Sourcing options
Berberine product picks
Recommendation status
Product recommendations are not shown for this profile because the current site safety and monetization policy does not permit them.
Product form & quality guidelines
When sourcing Berberine, verify the label for:
- Standardized Extract: Confirm active content percentages on the supplement facts panel (e.g. standardized to specific marker compounds) rather than simple raw herb weights.
- Third-Party Testing: Look for independent purity labels (USP, NSF, ConsumerLab, or Eurofins) to ensure the product is free from heavy metals, solvents, and contaminants.
- Form Bioavailability: Ensure the form matches evidence-supported configurations (e.g. chelated bisglycinate/glycinate for magnesium, micronized monohydrate for creatine) for optimal onset and digestion tolerance.
Safety first · Harm reduction
This information is educational and not medical advice. Start low, avoid risky combinations, and consult a licensed clinician before making health decisions—especially if you use medications, have diagnosed conditions, or are pregnant/breastfeeding.
Learn how we evaluate confidence, safety, and intensity on the methodology page.
Editorial Review
Checked against primary sources, cited evidence, and contraindication language before publication. Evidence claims, safety language, and affiliate modules are reviewed independently. Not personal medical advice.
Help improve this profile
Was this useful for your research?
These controls record only the page and the structured choice you make when analytics consent is enabled. Please don’t include personal medical information in research requests.
Was this evidence summary clear?
Did you find what you were researching?